GlassScriptPhysician profile
Kamyar Madani
NPI 1437295193
$3,447.82
in general payments reported to CMS, 2019-2025
20 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $233 · 2021: $385 · 2022: $243 · 2023: $759 · 2024: $547 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.52 |
| Education | $144.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $623.36 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $436.89 | 2019-2024 | Veltassa |
| Travere Therapeutics, INC. | $402.02 | 2020-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $225.14 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $221.20 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $195.08 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $181.08 | 2019-2025 | Rayaldee |
| Amgen INC. | $171.15 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $167.87 | 2023-2025 | |
| Horizon Therapeutics Plc | $139.66 | 2020-2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $126.97 | 2019-2025 | Velphoro, Velphoro |
| Medtronic, INC. | $112.29 | 2024 | Endo Gia Ultra |
| Akebia Therapeutics INC | $91.03 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.03 | 2024-2025 | Jardiance |
| Scpharmaceuticals INC. | $81.97 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $66.93 | 2019-2023 | Injectafer |
| Calliditas Therapeutics US INC. | $42.59 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $33.28 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $28.54 | 2023 | |
| Mallinckrodt Enterprises LLC | $15.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamyar Madani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.